Wu HX, Pan YQ, He Y, Wang ZX, et al. Clinical Benefit of First-Line Programmed Death-1 Antibody Plus Chemotherapy in Low Programmed Cell Death Ligand 1-Expressing Esophageal Squamous Cell Carcinoma: A Post Hoc Analysis of JUPITER-06 and Meta-Analysis. J Clin Oncol 2022 Dec 6:JCO2201490. doi: 10.1200/JCO.22.01490.
PMID: 36473145